Ainos Inc - Company Profile
Powered by 
All the data and insights you need on Ainos Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Ainos Inc Strategy Report
- Understand Ainos Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Ainos Inc (Ainos), formerly Amarillo Biosciences Inc, develops biologics for the treatment of human and animal diseases. It develops innovative therapeutic candidates for the treatment of diseases such as influenza, hepatitis C, thrombocytopenia, neoplastic, viral diseases, autoimmune disorders and other indications using its core technology (proprietary low dose form) of natural human interferon alpha. Its product portfolio includes COVID-19 point-of-care test such as antigen rapid test, molecular rapid test and VOC-based point-of-care. The company primarily operates in the US and supplies its product and medical equipment in Taiwan, People's Republic of China, Hong Kong through its branches and provides food supplements and nutraceuticals in the Asian markets. Ainos is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
8880 Rio San Diego Drive, Ste. 800, California, 92108
Website
www.ainos.com
Telephone
1 858 8692986
No of Employees
46
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AIMD (NASD)
Revenue (2022)
$122,100
-96.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
1.7%
(2022 vs 2021)
Market Cap*
$6.3M
Net Profit Margin (2022)
XYZ
-2,733.7%
(2022 vs 2021)
* As of and is in US$
Ainos Inc premium industry data and analytics
Products and Services
| Products |
|---|
| COVID-19 POCT: |
| Molecular Rapid Test |
| Antigen Rapid Test |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In August, the company signed an agreement with Nisshinbo Micro Devices Inc. and Taiwan Inabata Sangyo Co. to co-develop a volatile organic compound sensing platform. |
| 2022 | Contracts/Agreements | In August, the company signed an agreement with Swiss Pharmaceutical Co., Ltd. to test, manufacture and package the company's VELDONA GMP clinical batch and GMP commercial batch product candidates for the company's planned clinical trials. |
| 2021 | Contracts/Agreements | In December, the company and InnoPharmax Inc entered into an agreement for the development and commercialization of products for the treatment of infectious diseases, immunology, and oncology. |
Competitor Comparison
| Key Parameters | Ainos Inc | Regeneron Pharmaceuticals Inc | AIM ImmunoTech Inc | Hoffmann-La Roche Inc | InterMune Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Diego | Tarrytown | Ocala | Essex County | Brisbane |
| State/Province | California | New York | Florida | New Jersey | California |
| No. of Employees | 46 | 13,450 | 26 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Chun-Hsien Tsai | Chief Executive Officer; Chairman | Executive Board | 2021 | - |
| Meng-Lin Sung | Chief Financial Officer | Senior Management | 2023 | - |
| Jack Lu | Director - Corporate Development | Senior Management | 2021 | - |
| Selin Pan | Head - Marketing | Senior Management | - | - |
| Lawrence K. Lin | Executive Vice President - Operations | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer